NEW YORK (GenomeWeb News) – Agendia said today it has raised $65 million in a private round of equity financing.

The funds will be used to further expand the company's Symphony suite of breast cancer tests and the continued development of "our personalized medicine pipeline," Agendia CEO David Macdonald said in a statement. The company recently launched its Symphony suite in a formalin-fixed, paraffin-embedded format, and will soon launch its ColoPrint recurrence test for stage II colon cancer prognosis and prediction, he added.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: mouse genome functional analysis, more sensitive chromatin immunoprecipitation, and more.

The Center for Data Innovation and HealthITNow argue for re-building of genomic research infrastructure.

A Senate committee has unanimously approved a bill to require articles resulting from federally funded projects to be made publicly available, according to ScienceInsider.

The US is heading toward another budget showdown, Nature News says.